Arcadia Biosciences, Inc.
RKDAConsumer DefensiveNASDAQPackaged Foods · Last scanned Oct 19, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of Oct 16
Part of the consumer defensive sector, Arcadia Biosciences, Inc. (RKDA) is listed under Packaged Foods. Valued at $397K, RKDA is a micro-cap name in its sector. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients.
Market Cap
$397,037
Beta
0.55
P/E (TTM)
—
P/E (Fwd)
-0.13
EPS (TTM)
$-4.55
EPS (Fwd)
$-1.28
ROE
-430.9%
ROA
-34.8%
Cash
$4.2M
Total Debt
$0
Free CF
-$868,500
52W Change
-96.7%
Annual Financials
Cash vs Debt
Where RKDA stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, RKDA finished 79.01% below its 150-day moving average ($0.81) and 84.82% below its 200-day moving average ($1.12). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RKDA overbought or oversold?
At the October 19, 2026 close, RKDA's RSI(14) was 11.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Arcadia Biosciences, Inc. reports $4.2M in cash and $0 in total debt. Free cash flow is running at -$868K, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -430.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $7.4M (2022) to $4.9M (2025), a 35% decline worth watching.
With a beta below 0.7, Arcadia Biosciences, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Arcadia Biosciences, Inc. and its sector.